Anemia

FDA approves Aranesp for anemia associated with chemotherapy

Published in Cancer Weekly, August 27th, 2002

Amgen (AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved Aranesp (darbepoetin alfa) for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies.

Aranesp is a recombinant erythropoietic protein (proteins that stimulate production of oxygen-carrying red blood cells) that requires fewer injections than existing treatment.

Amgen revolutionized anemia treatment with the discovery of recombinant human erythropoietin in 1984, which led to the development of Epoetin alfa, currently marketed as EPOGEN and Procrit. Building on this heritage, Amgen created Aranesp, which was developed to simplify anemia...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-08-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry